Holger Scheible

Overexpression, purification and characterization of SimL, an amide synthetase involved in simocyclinone biosynthesis

Thomas Luft, Shu-Ming Li, Holger Scheible et al. · Archives of Microbiology · 2005 · 31 citations

Life Sciences, Biochemistry, Molecular Biology +9

<i>In vitro</i>metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS

Bernd Kammerer, Holger Scheible, Gabriela Zurek et al. · Xenobiotica · 2007 · 27 citations

Life Sciences, Biochemistry, Pharmacology +14

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients

Oliver von Richter, Giorgio Massimini, Holger Scheible et al. · British Journal of Clinical Pharmacology · 2016 · 26 citations · Full text

Medicine, Oncology, Pharmacology +14

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

Andreas Johne, Holger Scheible, Andreas Becker et al. · Investigational New Drugs · 2020 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Metabolism and disposition of the αv‐integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Andreas Becker, Oliver von Richter, Andreas Kovar et al. · The Journal of Clinical Pharmacology · 2015 · 22 citations

Pharmacy, Pharmacokinetics, Pharmacology +14